REFRACTORY NON-HODGKIN LYMPHOMA

This study tests a new drug called BGB-21447 for people with certain blood cancers (like lymphoma and leukemia) that have returned or not improved after prior therapy. The main goals are to find the safest dose and see if the drug can shrink tumors. About 112 participants will re…

This study tests a new drug called 9-ING-41, given alone or with chemotherapy, in adults with advanced cancers that have stopped responding to standard treatments. The goal is to see if the drug is safe and can help control the cancer. About 350 people with various cancer types, …

This study tested a drug called larotrectinib in children and young adults (ages 1 to 21) with advanced or returning cancers that have a specific genetic change called an NTRK fusion. The goal was to see if the drug could shrink tumors or stop them from growing. The study include…

This study tests a drug called ulixertinib in children and teens with advanced solid tumors, lymphoma, or histiocytic disorders that have a specific genetic change in the MAPK pathway. The goal is to see if the drug can shrink or stop the growth of these cancers. About 20 partici…

This study tests whether giving a targeted drug (brentuximab vedotin) weekly, with or without another immune-boosting drug (nivolumab), can shrink tumors in people with CD30+ lymphoma that has come back or stopped responding to standard treatment. About 28 adults with relapsed or…

This study tests a drug called ivosidenib (AG-120) in children and young adults (ages 1-21) whose cancers have a specific IDH1 gene change and have come back or not responded to standard treatment. The drug works by blocking a faulty signal that helps cancer grow. The main goal i…

This early-stage trial is testing a combination of two drugs, tazemetostat and belinostat, for people with lymphoma that has returned or stopped responding to standard treatments. The study aims to find the safest dose and see if the combination can shrink or stabilize the cancer…

This study tests a drug called selpercatinib (LOXO-292) in children and young adults (ages 1 to 21) with advanced cancers that have a specific genetic change in the RET gene. The goal is to see if the drug can shrink tumors or stop them from growing. The trial is for patients who…

This study tested a drug called erdafitinib in children and young adults (ages 1 to 21) whose cancers had come back or were not responding to treatment. The drug targets cancers with specific changes in FGFR genes. The main goal was to see if the drug could shrink tumors. About 2…

This study tested the drug ensartinib in 13 children and young adults (ages 1–21) whose cancers had come back or did not respond to treatment and had specific ALK or ROS1 gene changes. The goal was to see if the drug could shrink or stop tumor growth. While the drug targets cance…

This early-phase study looks at whether giving low-dose radiation before CAR T-cell therapy is practical and safe for people with B-cell lymphoma that has returned or not responded to treatment. About 33 adults will receive radiation to shrink tumors while waiting for their CAR T…

This study tests the drug tipifarnib in children and young adults (ages 1 to 21) whose advanced solid tumors, lymphoma, or related cancers have a specific change in the HRAS gene. The goal is to see if tipifarnib can shrink or stop the growth of these hard-to-treat cancers. Parti…

This early-phase trial tests the safety and correct dose of combining two cancer drugs, loncastuximab tesirine and venetoclax, for adults with relapsed or refractory B-cell non-Hodgkin lymphoma. About 23 participants will receive the combination to see how well it is tolerated an…

This early-phase trial is testing a combination of two drugs—selinexor and choline salicylate—in 22 adults with certain blood cancers (lymphoma, multiple myeloma, or histiocytic/dendritic cell tumors) that have come back or not responded to prior treatment. The main goal is to fi…

This early-phase study tests two drugs, pevonedistat and ibrutinib, together in people with chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma that has returned or no longer responds to standard therapy. The main goal is to find the safest dose and understand side effects…

This study screens children and young adults (ages 1–21) with advanced solid tumors, lymphomas, or related disorders that have come back or not responded to standard therapy. Researchers analyze the genetic makeup of each patient's tumor to find specific mutations that can be tar…